Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

July 29, 2022

Study Completion Date

July 29, 2022

Conditions
Head and Neck CancerHead and Neck NeoplasmsHead and Neck Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Enoblituzumab

Anti-B7-H3 antibody

BIOLOGICAL

Retifanlimab

Anti-PD-1 antibody

BIOLOGICAL

Tebotelimab

PD-1 X LAG-3 bispecific DART molecule

Trial Locations (42)

1145

Uzsoki Street Hospital, Budapest

1373

MHAT Nadezhda, Medical Oncology, Sofia

1527

UMHAT Tsarisa Yoanna - ISUL, Sofia

1632

MHAT Serdica, Panagyurishte

2065

Royal North Shore Hospital, Sydney

2170

Liverpool Hospital, Liverpool

2298

Calvary Mater Newcastle, Waratah

3168

Monash Health, Medical Oncology Department, Ruse

3220

Andrew Love Cancer Centre, Barwon Health, Geelong

4215

Icon Cancer Centre Southport, Southport

4500

MBAL Uni Hospital, Pleven

5700

Dept of Oncology, Bekec County Hosp, Gyula

5800

UMHAT Georgi Stranski Medical Oncology Department, Sofia

6150

Fiona Stanley Hospital, Murdoch

7002

Complex Oncology Center Ruse Ltd., Dobrich

7100

Dept of Oncology, Tolna County Hospital, Szekszárd

9300

COC Dobrich, Sofia

15027

The Ewa Pilecka Department of Clinical Oncology, Bialystok

15232

University of Pittsburgh Medical Center- Hillman Cancer Center, Pittsburgh

19104

University of Pennsylvania - Abramson Cancer Center, Philadelphia

21029

Communal Nonprofit Enterprise Podilsky Regional Center of Oncology, Vinnytsia

21201

University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore

25000

"Communal Non-profit Enterprise Regional Clinical Oncology Center of Kirovohrad Regional Council,", Kropyvnytskyi

27514

University of North Carolina - Lineberger Cancer Center, Chapel Hill

28040

Hospital Clínico San Carlos, Madrid

31008

Clinica Universidad de Navarra, Pamplona

40022

"Municipal Non-Profit Enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Dispensary", Sumy

41009

Hospital Universitario Virgen de la Macarena, Seville

48109

University of Michigan, Ann Arbor

49102

"Communal Non-profit Enterprise City Clinical Hospital#4 of Dnipro City", Dnipro

61070

"Communal Non-Profit Enterprise Regional Center of Oncology, Oncosurgical Department of Head and Neck", Kharkiv

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

01106

Bajcsy-Zsilinszky Korhaz, Budapest

04032

Dept of Oncology, University of Debrecen, Debrecen

80-214

Uniwersyteckie Centrum Kliniczne, Gdansk

44-102

I Clinics of Radiotherapy and Chemiotherapy; The Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice

05-410

Biokinetica, Józefów

Unknown

Clinics of Head and Neck Cancer, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw

06080

Complejo Hospitalario Universitario de Badajoz, Badajoz

08035

Hospital Universitario Vall D'Hebrón, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

03115

Kyiv City Clinical Oncological Centre, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MacroGenics

INDUSTRY